Acceptance follows resolution of third-party fill/finish manufacturing issues FDA decision expected by July 10, 2025 TARRYTOWN, N.Y., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc.

Acceptance follows resolution of third-party fill/finish manufacturing issuesFDA decision expected by July 10, 2025 TARRYTOWN, N.Y., Feb. 11, ...

Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what ...

Veru's experimental drug helps older obese patients on Wegovy preserve muscle January 27, 2025 Medical data research company Truveta said on Monday that Regeneron Pharmaceuticals , Illumina and 17 ...

In terms of treatment, the WHO in 2022 recommended two life-saving medicines, Inmazeb and Ebanga, for the Zaire strain. There are currently no approved treatments or vaccines for the Sudan strain.

In terms of treatment, the WHO in 2022 recommended two life-saving medicines, Inmazeb and Ebanga, for the Zaire strain. There are currently no approved treatments or vaccines for the Sudan strain.

Who Are The Key Players In The Inmazeb Market? Major players shaping the Inmazeb market include Regeneron Pharmaceuticals Inc. Industry transformations, innovative research and advancement in ...

Regeneron Pharmaceuticals, Inc. (REGN) Securities Class Action: The litigation is focused on the propriety of Regeneron’s statements about its compliance with applicable rules and regulations ...

SAN FRAN­CIS­CO — Just over 20 years ago, the peo­ple of Cal­i­for­nia vot­ed to spend bil­lions of dol­lars on an ex­cit­ing new idea to re­make med­i­cine … ...

NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN) of a class action securities ...